IRWD vs PHAT
IRWD: Ironwood Pharmaceuticals is a GI-focused biotech company commercializing the market-leading treatment for IBS-C and CIC, LINZESS, while advancing its late-stage pipeline asset for short bowel syndrome. PHAT: Phathom Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for gastrointestinal diseases, anchored by its potassium-competitive acid blocker platform.
Side-by-side fundamentals
| Metric | IRWD | PHAT | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $3.63 | $7.31 | |
| Market cap | $600M | $591M | |
| P/E as of 2026-10-20 | 4.59 | n/a | |
| Net margin FY2025, SEC XBRL | +8.1% | -126.3% | IRWD higher |
| Gross margin FY2025, SEC XBRL | n/a | +87.1% | |
| Operating margin FY2025, SEC XBRL | +33.3% | -91.4% | IRWD higher |
| ROA FY2025, SEC XBRL | +6.1% | -85.4% | IRWD higher |
| Revenue growth (YoY) FY2025, SEC XBRL | -15.7% | +216.9% | PHAT higher |
| Revenue CAGR (3y) SEC XBRL | -10.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.20 | 1.05 | |
| 1-year return as of 2026-10-20 close | +135.7% | -47.8% | IRWD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.